Les vraies contre-indications du BCG dans le traitement des tumeurs de vessie

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Progres En Urologie

• Publication date

  2010-03-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1016/S1166-7087(10)70025-7
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The fibronectin attachment protein of bacillus Calmette-Guerin (BCG) mediates antitumor activity

  2008cited by this paper
• Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa-IPV-HBV-Hib combination vaccine in healthy infants.

  2008cited by this paper
• Carcinome in situ vésical et urétral chez un patient transplanté rénal : échec de la BCG thérapie

  2008cited by this paper
• The role of the urinary epithelium in the pathogenesis of interstitial cystitis/prostatitis/urethritis.

  2007cited by this paper
• Increased Th1 and Th2 type cytokine production in patients with active tuberculosis.

  2007cited by this paper
• Radiotherapy for bladder cancer.

  2007cited by this paper
• Recommendations 2007 en Onco-Urologie

  2007cited by this paper
• Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses.

  2006cited by this paper
• [Intravesical BCG instillations for the treatment of superficial bladder tumours in renal transplant recipients].

  2006cited by this paper
• Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants.

  2006cited by this paper
• The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study.

  2006cited by this paper
• [Study of urothelial bladder tumours in renal transplant recipients].

  2006cited by this paper
• Safety and efficacy of intravesical bacillus Calmette-Guérin instillations in steroid-treated and immunocompromised patients.

  2006cited by this paper
• Human tuberculous granulomas induce peripheral lymphoid follicle‐like structures to orchestrate local host defence in the lung

  2004cited by this paper
• Interleukin 10 induced augmentation of delayed‐type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette‐Guérin (BCG) mediated antitumour activity

  2003cited by this paper
• Tolérance des vaccins : faits et spéculations

  2003cited by this paper
• Nonbilharzial bladder carcinoma complicating pregnancy--treatment with bacille Calmette-Guérin.

  2002influential reference
• Optimal treatment of systemic bacillus Calmette-Guérin infection: investigations in an animal model.

  2002cited by this paper
• Tolerability of bacille Calmette-Guérin maintenance therapy for superficial bladder cancer.

  2001cited by this paper
• Evaluation of the safety of intravesical BCG therapy in France: analysis of serious adverse events notified over a three-year period

  2001cited by this paper
• Evaluation de la tolérance de la BCG thérapie endovésicale en France : analyse des évènements indésirables graves notifiés sur une période de trois ans. Commentaire

  2001influential reference
• Everything you wanted to know about the bladder epithelium but were afraid to ask.

  2000cited by this paper
• Mécanismes d'action du BCG: vers une approche thérapeutique individualisée (ATI)?

  2000cited by this paper
• Intravesical bacille Calmette‐Guérin in the treatment of carcinoma in situ or high‐grade superficial bladder carcinoma after radiotherapy for bladder carcinoma

  1999cited by this paper
• Sensitivity of BCG to Modern Antibiotics

  1999cited by this paper
• Radiotherapy in bladder cancer.

  1999cited by this paper
• BCG immunotherapy of bladder cancer: 20 years on.

  1999cited by this paper
• Fluoroquinolones: a new treatment for tuberculosis?

  1998cited by this paper
• Effets tardifs de l'irradiation sur la vessie

  1997cited by this paper
• Fever of unknown origin.

  1997cited by this paper
• Changes in urinary cytokines and soluble intercellular adhesion molecule‐1 (ICAM‐1) in bladder cancer patients after Bacillus Calmette—Guérin (BCG) immunotherapy

  1995cited by this paper
• The effects of intravesical pretreatment with pentosan polysulfate on the bacillus Calmette-Guérin induced immune reaction of the guinea pig.

  1994cited by this paper
• Molecular confirmation of bacillus Calmette-Guérin as the cause of pulmonary infection following urinary tract instillation.

  1993influential reference

• [Guidelines from the cancer committee of the French Association of Urology (CC-AFU) for adequate intravesical instillations of Mitomycin C, Epirubicin, and BCG for non-muscle invasive bladder cancer].

  2022cites this paper
• About three cases of Mycobacterium bovis bone and joint infections after BCG therapy.

  2020cites this paper
• Évaluation des effets indésirables des instillations endovésicales par BCG: Implication potentielle de la souche utilisée ?

  2016cites this paper
• [Molecular, preclinical, and clinical comparative data regarding different strains of bacillus Calmette-Guérin (BCG): Review by the French Urological Association Oncology Committee (CCAFU)].

  2016cites this paper
• Complications dans les suites d’une BCG thérapie intravésicale : épidémiologie, description clinique et prise en charge

  2016cites this paper
• Comment suivre un schéma d’instillation du BCG en toute sécurité en 2013 ?

  2013cites this paper
• Intravesical bacillus Calmette-Guérin instillation therapy for non-muscle-invasive bladder cancer following solid organ transplantation

  2013cites this paper
• Diagnostic et prise en charge des événements indésirables survenant au décours des instillations endovésicales de BCG pour le traitement des tumeurs de vessie n’infiltrant pas le muscle (TVNIM) : revue du comité de cancérologie de l’Association française d’urologie

  2012cites this paper
• Radiochimiothérapie pour le traitement des cancers de vessie infiltrant le muscle : modalités, surveillance et résultats. Mise au point du comité de cancérologie de l’Association française d’urologie

  2012cites this paper
• [Guidelines for good practice of intravesical instillations of BCG and mitomycin C from the French national cancer committee (CC-AFU) for non-muscle invasive bladder cancer].

  2012cites this paper